Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study
We aimed to explore the efficacy of rechallenge after first-line immunotherapy in advanced gastric cancer (AGC) and to analyze the factors affecting prognosis based on clinical characteristics. Eighty-five AGC patients who underwent rechallenged after the failure of first-line treatment with immune...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2423479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850122908942204928 |
|---|---|
| author | Mengya Guo Wenhui Zhao Yue Chen Dan Zou Weiwei Peng Huanhuan Sha Guoren Zhou Ying Fang Bo Shen |
| author_facet | Mengya Guo Wenhui Zhao Yue Chen Dan Zou Weiwei Peng Huanhuan Sha Guoren Zhou Ying Fang Bo Shen |
| author_sort | Mengya Guo |
| collection | DOAJ |
| description | We aimed to explore the efficacy of rechallenge after first-line immunotherapy in advanced gastric cancer (AGC) and to analyze the factors affecting prognosis based on clinical characteristics. Eighty-five AGC patients who underwent rechallenged after the failure of first-line treatment with immune checkpoint inhibitors (ICIs) were retrospectively collected from July 2019 to December 2022 in Jiangsu Cancer Hospital. Potential factors affecting prognosis were analyzed by univariate and multivariate Cox analysis. Survival analysis was performed by Kaplan–Meier method and Log rank test. Stratified factors included human epidermal growth factor receptor 2 (HER-2) and programmed cell death-ligand 1 combined positive score (PD-L1 CPS). The objective response rate (ORR) was 15.3%, and the disease control rate (DCR) was 74.1%. The median progression-free survival (PFS) was 4.8 months. Results showed that patients in the I + C group had the best response. The ORR was 20.0% VS 8.7% in the I + C group and I + C + AAD group. The DCR was 78.0% VS 65.2%, and the median PFS was 6.7 VS 4.7 months [hazard ratio (HR): 0.55, 95% confidence interval (CI): 0.30–1.00, p = .022]. The ORR was 20.0% VS 8.3% in the I + C group and I + C + ADC group. The DCR was 78.0% VS 75.0%, and the median PFS was 6.7 VS 4.4 months (HR: 0.59, 95%CI: 0.26–1.30, p = .112). The median PFS was 4.7 VS 4.4 months in the I + C + AAD group and I + C + ADC group (HR: 1.21, 95%CI: 0.60–2.47, p = .580). Adverse events (AEs) were found in 34 patients, mainly including leukopenia 9 (10.6%), and neutropenia 8 (9.4%). The incidence of grade 3–4 AEs was 8.2%. There were no drug-related deaths and all AEs were manageable. Rechallenge after first-line immunotherapy showed good survival benefit and acceptable safety in the therapy of AGC. Especially for patients with HER-2-positive and PD-L1 CPS ≥ 1%, rechallenge may be an effective treatment modality. |
| format | Article |
| id | doaj-art-379af2d51e46406f9b801eac199842e7 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-379af2d51e46406f9b801eac199842e72025-08-20T02:34:43ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2423479Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world studyMengya Guo0Wenhui Zhao1Yue Chen2Dan Zou3Weiwei PengHuanhuan ShaGuoren Zhou4Ying FangBo ShenDepartment of Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, ChinaWe aimed to explore the efficacy of rechallenge after first-line immunotherapy in advanced gastric cancer (AGC) and to analyze the factors affecting prognosis based on clinical characteristics. Eighty-five AGC patients who underwent rechallenged after the failure of first-line treatment with immune checkpoint inhibitors (ICIs) were retrospectively collected from July 2019 to December 2022 in Jiangsu Cancer Hospital. Potential factors affecting prognosis were analyzed by univariate and multivariate Cox analysis. Survival analysis was performed by Kaplan–Meier method and Log rank test. Stratified factors included human epidermal growth factor receptor 2 (HER-2) and programmed cell death-ligand 1 combined positive score (PD-L1 CPS). The objective response rate (ORR) was 15.3%, and the disease control rate (DCR) was 74.1%. The median progression-free survival (PFS) was 4.8 months. Results showed that patients in the I + C group had the best response. The ORR was 20.0% VS 8.7% in the I + C group and I + C + AAD group. The DCR was 78.0% VS 65.2%, and the median PFS was 6.7 VS 4.7 months [hazard ratio (HR): 0.55, 95% confidence interval (CI): 0.30–1.00, p = .022]. The ORR was 20.0% VS 8.3% in the I + C group and I + C + ADC group. The DCR was 78.0% VS 75.0%, and the median PFS was 6.7 VS 4.4 months (HR: 0.59, 95%CI: 0.26–1.30, p = .112). The median PFS was 4.7 VS 4.4 months in the I + C + AAD group and I + C + ADC group (HR: 1.21, 95%CI: 0.60–2.47, p = .580). Adverse events (AEs) were found in 34 patients, mainly including leukopenia 9 (10.6%), and neutropenia 8 (9.4%). The incidence of grade 3–4 AEs was 8.2%. There were no drug-related deaths and all AEs were manageable. Rechallenge after first-line immunotherapy showed good survival benefit and acceptable safety in the therapy of AGC. Especially for patients with HER-2-positive and PD-L1 CPS ≥ 1%, rechallenge may be an effective treatment modality.https://www.tandfonline.com/doi/10.1080/21645515.2024.2423479Advanced gastric cancerimmune checkpoint inhibitorsrechallengeefficacysafety |
| spellingShingle | Mengya Guo Wenhui Zhao Yue Chen Dan Zou Weiwei Peng Huanhuan Sha Guoren Zhou Ying Fang Bo Shen Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study Human Vaccines & Immunotherapeutics Advanced gastric cancer immune checkpoint inhibitors rechallenge efficacy safety |
| title | Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study |
| title_full | Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study |
| title_fullStr | Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study |
| title_full_unstemmed | Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study |
| title_short | Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study |
| title_sort | efficacy of rechallenge after first line immunotherapy for advanced gastric cancer a retrospective real world study |
| topic | Advanced gastric cancer immune checkpoint inhibitors rechallenge efficacy safety |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2423479 |
| work_keys_str_mv | AT mengyaguo efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT wenhuizhao efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT yuechen efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT danzou efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT weiweipeng efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT huanhuansha efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT guorenzhou efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT yingfang efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy AT boshen efficacyofrechallengeafterfirstlineimmunotherapyforadvancedgastriccanceraretrospectiverealworldstudy |